{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Esophagus&page=3", "query": { "condition": "Cancer of the Esophagus", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 895, "total_pages": 90, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Esophagus&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Esophagus&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T07:53:31.080Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05705492", "title": "Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Advanced Biliary Tract Carcinoma", "Advanced Esophageal Carcinoma", "Metastatic Esophageal Carcinoma", "Locally Advanced Colorectal Carcinoma", "Locally Advanced Esophageal Carcinoma", "Locally Advanced Gastric Carcinoma", "Metastatic Colorectal Carcinoma (mCRC)", "Advanced Lung Carcinoma", "Locally Advanced Hepatocellular Carcinoma" ], "interventions": [ { "name": "Olanzapine", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2024-07-17", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-09T07:53:31.080Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05705492" }, { "nct_id": "NCT05319730", "title": "A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "MK-4830", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Antihistamine", "type": "DRUG" }, { "name": "H2 Receptor Antagonist", "type": "DRUG" }, { "name": "Acetaminophen (or equivalent)", "type": "DRUG" }, { "name": "Dexamethasone (or equivalent)", "type": "DRUG" }, { "name": "Steroid Mouthwash (dexamethasone or equivalent)", "type": "DRUG" }, { "name": "Supportive care measures", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2023-05-16", "completion_date": "2029-04-10", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-09T07:53:31.080Z", "location_count": 5, "location_summary": "Tucson, Arizona • Los Angeles, California • East Syracuse, New York + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "East Syracuse", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05319730" }, { "nct_id": "NCT07070466", "title": "Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stomach Cancer Stage IV", "Esophagus Cancer", "Stomach Cancer" ], "interventions": [ { "name": "Ivonescimab", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-10-10", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-09T07:53:31.080Z", "location_count": 2, "location_summary": "Santa Monica, California • Boston, Massachusetts", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07070466" }, { "nct_id": "NCT00002930", "title": "PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Esophageal Cancer", "Lung Cancer" ], "interventions": [ { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "1996-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-18", "last_synced_at": "2026-10-09T07:53:31.080Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002930" }, { "nct_id": "NCT05592626", "title": "A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Genital Neoplasm, Female", "Urogenital Neoplasms", "Lung Neoplasm", "Neoplasms by Site", "Papillomavirus Infection", "Epstein-Barr Virus Infections", "Carcinoma", "Neoplasms", "Vulvar Neoplasms", "Vulvar Diseases", "Abdominal Neoplasm", "NSCLC (Non-small Cell Lung Cancer)", "Colorectal Cancer" ], "interventions": [ { "name": "STAR0602", "type": "DRUG" }, { "name": "Irinotecan (Camptosar)", "type": "COMBINATION_PRODUCT" }, { "name": "Docetaxel (Taxotere)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Marengo Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 366, "start_date": "2023-01-04", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-09T07:53:31.080Z", "location_count": 13, "location_summary": "Sacramento, California • Celebration, Florida • Miami, Florida + 10 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Celebration", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05592626" }, { "nct_id": "NCT02358863", "title": "Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Modified FOLFOX6", "type": "DRUG" }, { "name": "Docetaxel/Capecitabine", "type": "DRUG" }, { "name": "Cisplatin/Irinotecan", "type": "DRUG" }, { "name": "Cisplatin/Docetaxel", "type": "DRUG" }, { "name": "IRI/EPI", "type": "DRUG" }, { "name": "EPI/Docetaxel", "type": "DRUG" }, { "name": "Irinotecan/Docetaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2015-02", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2018-09-06", "last_synced_at": "2026-10-09T07:53:31.080Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02358863" }, { "nct_id": "NCT04907643", "title": "Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer Pain", "Visceral Pain", "Gastrointestinal Neoplasms", "Cancer of Gastrointestinal Tract", "Small Intestine Cancer", "Pancreas Cancer", "Liver Cancer", "Colon Cancer", "Biliary Tract Cancer", "Stomach Cancer", "Rectum Cancer", "Peritoneal Cancer", "Gastrointestinal Cancer Metastatic", "Gastrointestinal Cancers - Anus", "Gastrointestinal Cancers - Stomach", "Gastrointestinal Cancers - Colorectal", "Gastrointestinal Cancers - Small Intestine", "Small Intestine Cancer Stage III", "Small Intestine Cancer Stage IV", "Small Intestine Cancer, Recurrent", "Pancreas Cancer, Stage III", "Pancreas Cancer, Stage IV", "Pancreas Cancer, Metastatic", "Pancreas Cancer, Recurrent", "Liver Cancer Stage IIIa", "Liver Cancer Stage IIIb", "Liver Cancer Stage IIIc", "Liver Cancer Stage IV", "Colon Cancer Stage III", "Colon Cancer Stage IV", "Stomach Cancer Stage III", "Stomach Cancer Stage IV", "Stomach Cancer Recurrent", "Rectum Cancer, Recurrent", "Gastrointestinal Cancers - Liver", "Anal Cancer", "Anal Cancer Stage III", "Anal Cancer Stage IV", "Anal Cancer Recurrent", "Anal Cancer Metastatic", "Anal Cancer, Stage IIIA", "Anal Cancer, Stage IIIB", "Appendix Cancer", "Ampullary Cancer", "Bile Duct Cancer", "Bile Duct Cancer Stage III", "Bile Duct Cancer Stage IV", "Bile Duct Cancer Stage IVA", "Bile Duct Cancer Stage IVB", "Bile Duct Cancer Recurrent", "Carcinoid Tumor", "Carcinoid Tumor of Pancreas", "Carcinoid Tumor of Large Intestine", "Carcinoid Tumor of GI System", "Carcinoid Tumor of Colon", "Carcinoid Tumor of Liver", "Carcinoid Tumor of Cecum", "Carcinoid Tumor of Ileum", "Carcinoid Tumor of Rectum", "Carcinoid Tumor of the Small Bowel", "Carcinoid Tumor of the Stomach", "Large Intestine Cancer", "Esophagus Cancer", "Esophagus Cancer, Stage III", "Esophagus Cancer, Stage IV", "Esophagus Cancer, Recurrent", "Gallbladder Cancer", "Gallbladder Cancer Stage III", "Gallbladder Cancer Stage IV", "Gastric (Stomach) Cancer", "Neuroendocrine Tumor", "Peritoneum Cancer", "Rectal Cancer", "Esophagus Cancer, Stage I", "Esophagus Cancer, Stage II", "Gallbladder Cancer Stage I", "Gallbladder Cancer Stage II", "Bile Duct Cancer Stage I", "Bile Duct Cancer Stage II" ], "interventions": [ { "name": "PICO G2 4k", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 360, "start_date": "2021-10-05", "completion_date": "2027-03-16", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-10-09T07:53:31.080Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04907643" }, { "nct_id": "NCT04566393", "title": "Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Pancreatic Cancer", "Small Bowel Cancer", "Colorectal Cancer", "Melanoma", "Non Small Cell Lung Cancer", "Thyroid Cancer", "Bladder Cancer", "Head and Neck Cancer", "Gastric Cancer", "Esophageal Cancer", "Cholangiocarcinoma", "Ovarian Cancer", "Hepatocellular Carcinoma", "Glioblastoma", "MAPK Gene Mutation", "KRAS Activating Mutation", "BRAF Gene Mutation", "NRAS Gene Mutation", "HRAS Gene Mutation", "MEK Mutation", "ERK Mutation" ], "interventions": [ { "name": "Ulixertinib (BVD-523)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "xCures", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-09T07:53:31.080Z", "location_count": 26, "location_summary": "Mobile, Alabama • Arroyo Grande, California • Newport Beach, California + 19 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Arroyo Grande", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04566393" }, { "nct_id": "NCT00021138", "title": "Computer-Assisted Scheduling of Nicotine Inhaler Use in Participants Who Plan to Stop Smoking", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Esophageal Cancer", "Head and Neck Cancer", "Lung Cancer" ], "interventions": [ { "name": "smoking cessation intervention", "type": "BEHAVIORAL" }, { "name": "nicotine", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "Personal Improvement Computer Systems", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "67 Years", "sex": "ALL", "summary": "18 Years to 67 Years" }, "enrollment_count": null, "start_date": "2001-04", "completion_date": "2004-03", "has_results": false, "last_update_posted_date": "2013-05-15", "last_synced_at": "2026-10-09T07:53:31.080Z", "location_count": 1, "location_summary": "Reston, Virginia", "locations": [ { "city": "Reston", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00021138" }, { "nct_id": "NCT01191697", "title": "CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2011-02", "completion_date": "2024-08", "has_results": true, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-10-09T07:53:31.080Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01191697" } ] }